•
Mar 31, 2022

Quanterix Q1 2022 Earnings Report

Quanterix reported revenue growth, but gross margin fell short of expectations. The company is implementing changes to inventory management and quality processes to improve gross margins.

Key Takeaways

Quanterix Corporation announced financial results for the first quarter of 2022, with revenue in line with expectations but gross margin falling short. The company is implementing changes to improve gross margins.

Q1 revenue was in line with expectations and full-year goals.

Gross margin fell well short of expectations.

Implementing specific changes to inventory management and quality processes.

Focus on scaling with quality, innovation, and ability to translate ultra-sensitive biomarker detection.

Total Revenue
$29.6M
Previous year: $24.9M
+18.6%
EPS
-$0.49
Previous year: -$0.29
+69.0%
Gross Profit
$14.6M
Previous year: $14.1M
+3.6%
Cash and Equivalents
$375M
Previous year: $443M
-15.4%
Free Cash Flow
-$23.1M
Previous year: -$14.2M
+63.0%
Total Assets
$507M
Previous year: $533M
-4.9%

Quanterix

Quanterix

Forward Guidance

Quanterix is focused on scaling with quality, innovation, and translating ultra-sensitive biomarker detection to help researchers and pharmaceutical companies drive earlier disease detection, better prognoses, and enhanced treatment methods.